Basic Calan Sr Information

• INN (International Nonproprietary Name): Verapamil
• Brand Names Available In United Kingdom: Calan, Calan SR (USA); Isoptin, Isoptin SR (Europe, Canada); Verelan, Verelan PM (USA); Covera‑HS (USA); Tarka (USA/Canada); Vérapamil / Verapamilo / Verapamilum (France, Spain, Romania, Latin America).
• ATC Code: C08DA01 — C: Cardiovascular System; 08: Calcium Channel Blockers; D: Phenylalkylamine Derivatives; A01: Verapamil.
• Forms & Dosages: Immediate‑release tablets 40 mg, 80 mg, 120 mg; Extended‑release tablets 120 mg, 180 mg, 240 mg; Extended‑release capsules 120 mg, 180 mg, 240 mg.
• Manufacturers In United Kingdom: Pfizer (Calan SR noted in US), Abbott Laboratories, Knoll, Mylan, Sandoz and numerous generics; regional brands like Isoptin and generics are common in EU markets; check ANMDMR for Romanian distributors.
• Registration Status In United Kingdom: Approved by major regulators (EMA, FDA and national agencies) for hypertension, angina and arrhythmias; prescription‑only and included in clinical formularies.
• OTC / Rx Classification: Prescription‑only (Rx) medicine in all major markets.

Major 2022–2024 Studies

Main Outcomes

What did the latest trials actually show about verapamil?

Recent clinical reports from 2022–2024 confirm verapamil remains effective for supraventricular tachycardia and angina symptom control.

Randomised trials and pooled meta‑analyses comparing verapamil with diltiazem and dihydropyridine calcium channel blockers show similar anti‑ischaemic benefits across the class.

Verapamil’s phenylalkylamine profile produced greater negative chronotropy in those comparisons compared with dihydropyridines.

Extended‑release formulations continued to provide steady symptom control with fewer peak‑related effects than immediate‑release dosing.

Clinical practice audits in the UK note reduced first‑line use for uncomplicated hypertension compared with amlodipine.

However, verapamil remains a mainstay for arrhythmia rate control and selected angina patients where nodal suppression is desired.

Safety Observations

Are there new safety concerns that prescribers should know about?

Pooled analyses through mid‑2024 emphasise caution in older multimorbid patients because of bradycardia and hypotension risk.

Post‑marketing surveillance from regulatory bodies reiterates contraindications in advanced heart block and severe heart failure.

Common safety signals include increased constipation and peripheral oedema when verapamil is used with vasodilatory agents.

Clinically significant interactions with beta‑blockers remain an important hazard noted in multiple databases.

These findings support careful monitoring of heart rate, blood pressure and concomitant drugs at initiation and during titration.

Layman’s Explanation

How does verapamil help people with high heart rate or chest pain?

Verapamil calms the electrical signals that make the heart beat too fast.

It also relaxes the blood vessels a little, making it easier for the heart to get oxygen and reducing chest pain.

Patients often describe feeling less palpitations and fewer angina episodes after stable dosing.

Scientific Breakdown

What is happening at the cellular level when verapamil works?

Verapamil is a phenylalkylamine calcium‑channel blocker with cardiac‑selective activity on L‑type channels.

It slows AV nodal conduction and reduces heart rate (negative chronotropy) and contractility (negative inotropy).

These effects make verapamil useful for supraventricular arrhythmias and as part of angina management when nodal slowing is desirable.

Pharmacokinetics (ER Vs IR)

Immediate‑release tablets (40–120 mg) are absorbed quickly and typically require three times daily dosing for angina control.

Extended‑release tablets and capsules (120–240 mg) give steadier plasma concentrations and are used once or twice daily depending on the product.

Do not crush or chew extended‑release formulations as that disrupts controlled release and can increase adverse effects.

Metabolism & Elimination

Verapamil undergoes predominant hepatic metabolism and requires dose reduction in significant liver impairment.

Renal elimination of metabolites occurs but renal impairment rarely dictates the primary dose change.

ATC classification is C08DA01 and monitoring is advised in the elderly and those with hepatic disease.

United Kingdom Approvals

What is verapamil licensed for in the UK?

Verapamil is approved for hypertension, angina and certain supraventricular arrhythmias across major regulators including EMA and national agencies.

In UK practice verapamil is prescription‑only and used within these licensed indications.

Standard adult oral dosing examples include hypertension 180–240 mg/day (ER), angina 80–120 mg three times daily (IR) and arrhythmias 240–320 mg/day divided.

Choice of formulation and dose is guided by the indication and patient factors such as age and liver function.

Notable Off‑Label Trends

Are clinicians using verapamil beyond the licence sometimes?

Off‑label uses are relatively limited but include specialist paediatric arrhythmia management with weight‑based dosing.

There is also occasional niche use in cluster headache prophylaxis at specialist centres, though robust evidence is limited.

Any off‑label use should be supervised by cardiology due to the risk of heart block and hypotension.

General Dosing

How is verapamil usually started and adjusted?

Immediate‑release tablets are commonly available as 40 mg, 80 mg and 120 mg strengths and are taken multiple times daily.

Extended‑release options are provided as 120 mg, 180 mg and 240 mg and suit once‑daily or twice‑daily regimens.

Start low in elderly patients and titrate to effect, avoiding abrupt withdrawal.

Condition‑Specific Dosing

What doses are typical for hypertension, angina and arrhythmias?

For hypertension, ER 180–240 mg once daily or divided dosing is commonly used and adjusted for BP response.

For chronic angina, IR 80–120 mg three times daily or an ER alternative is used alongside other antianginal therapy.

For supraventricular arrhythmias, total daily doses are typically 240–320 mg in divided doses; IV verapamil is used in monitored acute settings.

Special populations: start ER 120 mg/day in older patients and reduce doses in hepatic impairment; paediatric use is specialist and weight‑based.

Contraindications

Who should not take verapamil?

Absolute contraindications include severe hypotension (systolic <90 mmHg), second‑ or third‑degree AV block unless paced, and sick sinus syndrome unless a pacemaker is present.

Severe heart failure and known hypersensitivity to verapamil or excipients are also contraindications.

Documenting a baseline ECG is wise before initiating therapy in higher‑risk patients.

Adverse Effects

What side effects are patients most likely to notice?

Constipation is the most commonly reported adverse effect and is often the reason for stopping treatment.

Other common effects include dizziness, headache, fatigue, peripheral oedema and nausea.

Serious risks include symptomatic bradycardia, severe hypotension and worsening heart failure in susceptible patients.

Overdose requires emergency treatment with supportive care, IV calcium, vasopressors or pacing where indicated.

Food Interactions

Do I need to avoid any foods while on verapamil?

No critical food restrictions exist but grapefruit juice can increase verapamil plasma levels and should be avoided or limited.

Consistent dosing with regard to meals helps steady absorption, especially with ER products.

Drug Combinations To Avoid

Which medicines pose a danger when combined with verapamil?

Combining verapamil with beta‑blockers risks additive negative chronotropy and AV block and should be avoided unless under close ECG monitoring.

Verapamil raises digoxin concentrations, so monitor digoxin levels when used together.

CYP3A4 inhibitors such as some azoles and macrolides can increase verapamil exposure and may require dose adjustment.

Statins metabolised by CYP3A4, for example simvastatin, can have increased levels with verapamil; consider alternatives or dose limits.

St John’s wort may reduce verapamil levels by induction and should be discussed with prescribers.

Survey Data

What do patients report about tolerability and effectiveness?

Patient‑reported outcome studies show verapamil gives good control of arrhythmia symptoms and angina for many people.

Extended‑release formulations are associated with better adherence because of once‑daily dosing and fewer peak effects.

Constipation and fatigue are the most commonly reported tolerability issues leading to discontinuation in surveys.

Forum Trends

What do online communities say about switching brands and side effects?

Forum discussions often mention brand confusion when switching between Calan SR, Isoptin SR and generics.

Many patients say ECG monitoring and clear counselling from clinicians reduces anxiety when starting therapy.

Practical patient advice includes reporting syncope or significant dizziness, not crushing ER tablets and carrying a detailed medicines list in emergencies.

Market Availability

Can I get verapamil easily in the UK?

Verapamil is supplied globally under multiple brands and generics and is prescription‑only across major markets.

Brands cited in production and distribution notes include Calan/Calan SR, Isoptin/Isoptin SR and many generics from Mylan and Sandoz.

NHS prescribing typically uses the generic INN to reduce cost and ensure supply continuity.

Pricing & Reimbursement

How does cost and NHS coverage work for patients?

Generic verapamil tablets are generally low‑cost and reimbursed under usual NHS prescription rules; prescription charges apply unless exempt.

Branded ER products can be more expensive and may be hospital‑formulary managed for IV or monitored switches.

Pharmacies should check local stock and supply hubs for shortages and advise on clinically appropriate alternatives.

Comparison Table

Which drugs are the closest alternatives to verapamil?

Diltiazem offers an intermediate profile with rate‑control effects and generally less constipation than verapamil.

Amlodipine is a dihydropyridine that is often preferred for hypertension in UK primary care due to strong vasodilation and minimal negative chronotropy.

Beta‑blockers deliver rate control and anti‑ischaemic benefits but are unsuitable for patients with reactive airways disease.

Pros And Cons

How do I decide between verapamil and alternatives?

Verapamil is advantageous for AV nodal suppression and angina relief but carries higher bradycardia and constipation risk.

Amlodipine is better tolerated for most hypertension patients but causes more peripheral oedema.

Diltiazem is a middle ground and is often considered when some nodal control is required without the full cardiac depressant effects of verapamil.

Licencing & Approvals

What is the regulatory status that clinicians should note?

Verapamil (ATC C08DA01) is approved by EMA, FDA and national regulators for hypertension, angina and arrhythmias and is prescription‑only in the UK.

Clinicians should consult the SmPC and BNF for up‑to‑date prescribing advice and contraindications.

Pharmacovigilance Notes

What safety reporting and monitoring points are emphasised by regulators?

MHRA and EMA reports continue to highlight contraindications such as advanced heart block and severe heart failure.

Post‑marketing surveillance tracks symptomatic bradycardia and overdose incidents and supports caution in elderly, multimorbid patients.

When switching between ER brands consider bioequivalence and counsel patients about differences in dosing schedules.

Common Patient Questions

Can I get Calan SR in the UK and what should I do if I miss a dose?

Calan SR as a brand is primarily noted in the US; in the UK prescribers commonly use Isoptin SR or generic verapamil ER when an extended‑release option is required.

If you miss a dose, take it when you remember unless it is near the time for the next dose; do not double up.

Do not crush or chew extended‑release tablets as this destroys the controlled release mechanism.

Clinician Queries

What monitoring should clinicians perform at initiation and during titration?

Check baseline ECG, heart rate and blood pressure before starting verapamil and reassess within 1–2 weeks after dose changes.

Review concomitant medicines for interactions with beta‑blockers, digoxin and CYP3A4 inhibitors and adjust therapy accordingly.

How To Identify Formulations

How can pharmacy staff and patients tell IR and ER products apart?

Immediate‑release tablets are usually smaller, may be scored and come in strengths of 40–120 mg for multiple daily dosing.

Extended‑release tablets and capsules in 120–240 mg strengths are larger and often marked SR or ER or with brand names such as Isoptin SR.

Dosing Visual Cues

What simple cues help avoid dispensing errors?

ER tablets are larger and elongated and are not for splitting or crushing.

IR tablets are smaller and may be scored for halving when clinically appropriate.

Pharmacy staff should keep ER and IR stock separated and counsel patients to maintain consistent timing for ER doses.

Best Practices For Storage

How should verapamil be stored in pharmacy and at home?

Store verapamil at 15–30°C away from moisture and heat and keep it out of reach of children.

Do not refrigerate and avoid storing in bathrooms where humidity is high.

Supply‑Chain Considerations

What should pharmacies watch for regarding availability?

Multiple manufacturers (Pfizer, Mylan, Sandoz) reduce single‑source risk but brand availability varies by region.

Monitor NHS supply notices for local shortages and have clinically suitable alternatives ready for substitution.

Initiation Checklist

What is a safe practical checklist before starting verapamil?

Confirm the indication, obtain baseline ECG, record blood pressure and heart rate and review all current medicines for interactions.

Assess liver function and start lower doses in older or frail patients.

Monitoring & Deprescribing

How should clinicians monitor and stop verapamil safely?

Recheck BP and heart rate within 1–2 weeks of starting or after dose changes and repeat ECG if symptomatic or when combining nodal blockers.

Deprescribing should be gradual where possible to avoid rebound tachycardia and should be coordinated with cardiology for arrhythmia patients.

Patient counselling should cover not crushing ER tablets, avoiding grapefruit juice and reporting fainting or severe dizziness.

Consolidated FAQ

Is Calan SR available in the UK?

Calan SR is primarily a US brand; in the UK similar ER products include Isoptin SR and generic verapamil ER, and prescribers usually use the INN verapamil.

Can verapamil be used in pregnancy?

Use in pregnancy is not routinely recommended and should only be considered when necessary under specialist advice.

What to do in overdose?

Seek emergency medical attention; supportive care can include IV calcium, vasopressors and pacing as required.

Patient Counselling Points

What key tips improve safety and adherence?

Advise patients not to crush or chew ER tablets and to keep dosing times consistent for ER products.

Tell patients to report symptoms of slow heartbeat, dizziness or fainting promptly.

Encourage carrying a medicines list for emergencies and checking with the pharmacist before starting new OTC or herbal products.

How To Order And Access

How can patients obtain verapamil quickly and discreetly?

In our online pharmacy, calan sr is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

For safe practice, advise patients that UK clinical prescribing normally requires a valid prescription and that pharmacists will check suitability and interactions before supply.

Visual Checklist For Content Creators

What images and labels help patients pick the right product?

Use pictograms showing ER tablets labelled SR/ER and a warning icon for “Do Not Crush”.

Include images of small IR tablets with multiple daily dosing arrows and larger ER tablets with once‑daily clocks.

Pharmacy Handling Checklist

What are the quick handling rules in the dispensary?

Confirm brand substitution is clinically appropriate, segregate ER and IR stock and counsel patients about constipation, dizziness and interaction risks.

Storage And Transport Best Practices

What should couriers and patients do when transporting verapamil?

Keep products dry and avoid prolonged exposure to high temperatures during transit.

Follow manufacturer storage instructions and check expiry on delivery before handing to the patient.

Initiation And Titration Summary

How should clinicians start and titrate therapy safely?

Begin with lower ER doses in elderly patients, review concomitant therapy for beta‑blockers and digoxin, and schedule a follow‑up for BP/HR within 1–2 weeks.

Delivery Across United Kingdom